Chronic TGF-β exposure drives stabilized EMT, tumor stemness, and cancer drug resistance with vulnerability to bitopic mTOR inhibition

• DOI: 10.1126/scisignal.aau8544
• Publication Date: 2019-02-27T00:25:12Z
• Authors: Yoko Katsuno; Dominique Stephan...; Ziyang Zhang; Kevan M. Shokat; Rosemary J. Akhurst; Kohei Miyazono; Rik Derynck
• Keywords: 0301 basic medicine; Epithelial-Mesenchymal Transition; Cells; Knockout; Drug Resistance; 610; Antineoplastic Agents; Dioxoles; Mice, SCID; Cell Transformation; SCID; Cell Line; Mice; 03 medical and health sciences; Rare Diseases; Stem Cell Research - Nonembryonic - Human; Mice, Inbred NOD; Transforming Growth Factor beta; Breast Cancer; 2.1 Biological and endogenous factors; Animals; Humans; Cells, Cultured; Cancer; Cell Line, Transformed; Mice, Knockout; Neoplastic; Cultured; TOR Serine-Threonine Kinases; Biological Sciences; Stem Cell Research; Xenograft Model Antitumor Assays; 3. Good health; Cell Transformation, Neoplastic; Transformed; 5.1 Pharmaceuticals; Drug Resistance, Neoplasm; Biochemistry and cell biology; Benzamides; Neoplastic Stem Cells; Women's Health; Neoplasm; Inbred NOD; Stem Cell Research - Nonembryonic - Non-Human; Female; Biochemistry and Cell Biology; Signal Transduction

Inhibiting mTOR may reverse TGF-β–induced metastatic traits and drug resistance in carcinoma cells.